- According to Reuters, a whistleblower's email sent to top management at GlaxoSmithKline (NYSE:GSK) alleges improper payments were made to Romanian doctors between 2009 and 2012 in order to influence prescribing for GSK's drugs, including Avodart, Duodart and Requip.
- According to the email, the physicians were paid for speaking engagements, but in three of six cases, they did not speak at all. The other three gave only one speech each despite receiving multiple payments.
- The company stated it will look "very thoroughly" into the claims, which allegedly occurred before its December 2013 pledge to stop paying doctors for speaking on its behalf.
- The firm is currently investigating suspected bribery in Poland, the United Arab Emirates, Lebanon, Syria and Iraq. It paid a $483M fine to Chinese authorities last year to settle allegations there.